Islet organoids: a new hope for islet transplantation in diabetes
Diabetes mellitus, including Type 1 diabetes (T1D) and advanced Type 2 diabetes (T2D), remains a major global health challenge due to the destruction or dysfunction of insulin-producing β-cells. Islet transplantation offers a promising therapeutic strategy. However, it is limited by organ shortage g...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1540209/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592426127065088 |
|---|---|
| author | Xuemei Yu Chengkong Liu Zheng Kuang Siyuan Song Limin Tian Yi Wang Yi Wang |
| author_facet | Xuemei Yu Chengkong Liu Zheng Kuang Siyuan Song Limin Tian Yi Wang Yi Wang |
| author_sort | Xuemei Yu |
| collection | DOAJ |
| description | Diabetes mellitus, including Type 1 diabetes (T1D) and advanced Type 2 diabetes (T2D), remains a major global health challenge due to the destruction or dysfunction of insulin-producing β-cells. Islet transplantation offers a promising therapeutic strategy. However, it is limited by organ shortage globally and other risk factors. Recent advancements in organoid technology provide transformative solutions for islet regeneration. This review summarized three groundbreaking approaches: islet organoids differentiated from Procr+ pancreatic progenitor cells, chemically induced pluripotent stem cells (CiPSCs), and endoderm stem cells (EnSCs). Procr+ cells exhibit multipotency and potential for in vivo activation, offering a scalable and non-invasive strategy for β-cell regeneration. CiPSCs, reprogrammed via small molecules, enable personalized islet therapies with promising clinical outcomes, as demonstrated in T1D patients. EnSC-derived islets (E-islets) offer high differentiation efficiency and therapeutic efficacy, particularly for T2D patients with residual β-cell function. While each approach addresses specific challenges in islet transplantation, further research is needed to optimize scalability, immune compatibility, and long-term functionality. This review highlights the potential of organoid-based technologies to revolutionize diabetes treatment and pave the way for personalized, curative therapies. |
| format | Article |
| id | doaj-art-a29e531ef3da4027a627a0b91ca9972e |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a29e531ef3da4027a627a0b91ca9972e2025-01-21T08:37:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15402091540209Islet organoids: a new hope for islet transplantation in diabetesXuemei Yu0Chengkong Liu1Zheng Kuang2Siyuan Song3Limin Tian4Yi Wang5Yi Wang6Department of Clinical Nutrition, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Neuroscience, Baylor College of Medicine, Houston, TX, United StatesCenter for Geriatrics and Endocrinology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaCenter for Geriatrics and Endocrinology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaClinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDiabetes mellitus, including Type 1 diabetes (T1D) and advanced Type 2 diabetes (T2D), remains a major global health challenge due to the destruction or dysfunction of insulin-producing β-cells. Islet transplantation offers a promising therapeutic strategy. However, it is limited by organ shortage globally and other risk factors. Recent advancements in organoid technology provide transformative solutions for islet regeneration. This review summarized three groundbreaking approaches: islet organoids differentiated from Procr+ pancreatic progenitor cells, chemically induced pluripotent stem cells (CiPSCs), and endoderm stem cells (EnSCs). Procr+ cells exhibit multipotency and potential for in vivo activation, offering a scalable and non-invasive strategy for β-cell regeneration. CiPSCs, reprogrammed via small molecules, enable personalized islet therapies with promising clinical outcomes, as demonstrated in T1D patients. EnSC-derived islets (E-islets) offer high differentiation efficiency and therapeutic efficacy, particularly for T2D patients with residual β-cell function. While each approach addresses specific challenges in islet transplantation, further research is needed to optimize scalability, immune compatibility, and long-term functionality. This review highlights the potential of organoid-based technologies to revolutionize diabetes treatment and pave the way for personalized, curative therapies.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1540209/fullislet organoidsdiabetes treatmentProcr+ progenitorschemically induced pluripotent stem cells (CiPSCs)endoderm stem cells (EnSCs)β-cell regeneration |
| spellingShingle | Xuemei Yu Chengkong Liu Zheng Kuang Siyuan Song Limin Tian Yi Wang Yi Wang Islet organoids: a new hope for islet transplantation in diabetes Frontiers in Immunology islet organoids diabetes treatment Procr+ progenitors chemically induced pluripotent stem cells (CiPSCs) endoderm stem cells (EnSCs) β-cell regeneration |
| title | Islet organoids: a new hope for islet transplantation in diabetes |
| title_full | Islet organoids: a new hope for islet transplantation in diabetes |
| title_fullStr | Islet organoids: a new hope for islet transplantation in diabetes |
| title_full_unstemmed | Islet organoids: a new hope for islet transplantation in diabetes |
| title_short | Islet organoids: a new hope for islet transplantation in diabetes |
| title_sort | islet organoids a new hope for islet transplantation in diabetes |
| topic | islet organoids diabetes treatment Procr+ progenitors chemically induced pluripotent stem cells (CiPSCs) endoderm stem cells (EnSCs) β-cell regeneration |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1540209/full |
| work_keys_str_mv | AT xuemeiyu isletorganoidsanewhopeforislettransplantationindiabetes AT chengkongliu isletorganoidsanewhopeforislettransplantationindiabetes AT zhengkuang isletorganoidsanewhopeforislettransplantationindiabetes AT siyuansong isletorganoidsanewhopeforislettransplantationindiabetes AT limintian isletorganoidsanewhopeforislettransplantationindiabetes AT yiwang isletorganoidsanewhopeforislettransplantationindiabetes AT yiwang isletorganoidsanewhopeforislettransplantationindiabetes |